• The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • MG0003


    Enrollment Information

    Call (602) 406-6606 or E-Mail [email protected]

    Gregory W. Fulton Neuromuscular Center

    Learn More

    The purpose of this study is to assess the clinical efficacy, safety and tolerability of Rozanolixizumab, which is a type of antibody that helps breakdown harmful auto-antibodies in generalized myasthenia gravis patients.

    Rozanolixizumab will be administered through a 30-minute subcutaneous infusion (i.e. a small needle inserted under the skin) every week for 6 weeks, with a two month observation period. Overall, participants may be in the research study for about 19 weeks, with the option to continue for up to about 1 year in an open label extension study.

    Principal Investigator: Suraj Muley, MD

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.